Novel Biomarkers in Histopathology: Promising Targets for Precision Medicine

Mizika Chai^*
*Correspondence: Mizika Chai, Department of Internal Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan, Email:

Introduction

Histopathology has been instrumental in diagnosing and treating diseases, yet the need for precision medicine demands more specific and tailored approaches. Novel biomarkers have emerged as promising targets, enabling precise diagnosis, prognosis, and treatment selection. This review explores recent developments in identifying and utilizing novel biomarkers in histopathology for precision medicine applications. We discuss various types of biomarkers, their clinical significance, challenges, and future directions in integrating them into routine clinical practice. Histopathology remains a cornerstone of disease diagnosis, providing critical insights into tissue morphology and pathology.

However, conventional methods often lack the precision needed for personalized treatment decisions. With the rise of precision medicine, there is a growing need for biomarkers that can accurately stratify patients based on their disease characteristics and predict treatment response. Novel biomarkers hold the key to achieving this level of precision. Genetic alterations such as mutations, gene fusions, and copy number variations serve as important biomarkers in various diseases, including cancer. Techniques such as nextgeneration sequencing and fluorescence in situ hybridization allow for the detection of these genomic alterations, aiding in diagnosis, prognosis, and treatment selection.

Description

Epigenetic alterations, such as DNA methylation patterns and histone modifications, play a crucial role in disease pathogenesis. Detection methods such as bisulfite sequencing and chromatin immunoprecipitation sequencing allow for the identification of epigenetic biomarkers with diagnostic and prognostic implications. Liquid biopsies, including circulating tumor cells and cell-free nucleic acids, offer a non-invasive method for monitoring disease progression and treatment response. These biomarkers provide real-time information about tumor dynamics and the emergence of drug resistance, facilitating personalized treatment decisions [1-3].

Biomarkers such as programmed death-ligand 1 expression and tumorinfiltrating lymphocytes predict response to immune checkpoint inhibitors in cancer immunotherapy. Assessment of these biomarkers helps identify patients who are likely to benefit from immunotherapy and guides treatment decisions. Metabolic alterations in tumors, detected through metabolomics and imaging techniques, offer insights into tumor biology and response to therapy. Metabolic biomarkers may serve as early indicators of treatment efficacy or resistance, aiding in treatment monitoring and optimization.

Metabolic biomarkers refer to specific molecules or metabolic signatures that are indicative of physiological or pathological processes within the body. In histopathology, these biomarkers provide insights into the metabolic state of cells and tissues, aiding in disease diagnosis, prognosis, and treatment monitoring. Small molecules involved in metabolic pathways, such as glucose, amino acids, lipids, and organic acids. Alterations in metabolite levels can reflect changes in cellular metabolism associated with disease. Proteins involved in catalyzing metabolic reactions. Aberrant enzyme expression or activity may indicate metabolic dysregulation in diseases such as cancer.

Techniques like positron emission tomography and magnetic resonance spectroscopy allow for the visualization and quantification of metabolic processes in tissues, providing valuable information about tumor metabolism and response to therapy. Specific metabolic profiles can differentiate between disease states, aiding in the accurate diagnosis of conditions such as cancer and metabolic disorders [4,5]. Metabolic biomarkers may predict disease progression and patient outcomes. For example, certain metabolite profiles in tumor tissues can correlate with aggressiveness and metastatic potential.

Monitoring changes in metabolic biomarkers during treatment can assess treatment efficacy and guide therapeutic decisions. For instance, changes in glucose metabolism in tumors following chemotherapy or radiation therapy can indicate treatment response or resistance. Robust validation studies and standardization of assays are necessary to ensure the reliability and reproducibility of biomarker tests across different laboratories and platforms. Efforts are needed to integrate biomarker testing into routine clinical practice, including education and training for healthcare professionals and the development of guidelines for biomarker-based treatment decisions. Advanced computational methods are required for the analysis and interpretation of complex biomarker data. Collaboration between pathologists, bioinformaticians, and data scientists is essential to derive meaningful insights from biomarker analyses.

Conclusion

Novel biomarkers in histopathology hold tremendous promise for advancing precision medicine by enabling more accurate diagnosis, prognosis, and treatment selection. Overcoming challenges related to validation, standardization, and data interpretation will be crucial for integrating these biomarkers into routine clinical practice and improving patient outcomes across various diseases. Continued research and collaboration are needed to realize the full potential of novel biomarkers in precision medicine.

References

1. Alataki, Anastasia, Lila Zabaglo, Holly Tovey and Andrew Dodson, et al. "A simple digital image analysis system for automated Ki67 assessment in primary breast cancer." Histol 79 (2021): 200-209.

   Google Scholar, Crossref, Indexed at

2. Davey, Matthew G., Sean O. Hynes, Michael J. Kerin and Nicola Miller, et al. "Ki-67 as a prognostic biomarker in invasive breast cancer." Cancers 13 (2021): 4455.

   Google Scholar, Crossref, Indexed at

3. Robertson, Stephanie, Balazs Acs, Michael Lippert and Johan Hartman. "Prognostic potential of automated Ki67 evaluation in breast cancer: Different hot spot definitions versus true global score." Breast Cancer Res Treat 183 (2020): 161-175.

   Google Scholar, Crossref, Indexed at

4. Abubakar, Mustapha, Nick Orr, Frances Daley and Penny Coulson, et al. "Prognostic value of automated KI67 scoring in breast cancer: A centralised evaluation of 8088 patients from 10 study groups." Breast Cancer Res 18 (2016): 1-13.

   Google Scholar, Crossref, Indexed at

5. Cho, William C. "Digital Pathology: New Initiative in Pathology." Biomolecules 12 (2022): 1314.

   Google Scholar, Crossref, Indexed at